ストックスクリーナーアプリを入手
142.01
2.44%
4.71
アフターアワーズ：
142.73
0.72
+0.51%
前日終値:
$137.30
開ける：
$137.5
24時間の取引高:
237.24K
Relative Volume:
1.52
時価総額：
$5.69B
収益：
-
当期純損益:
$-77.61M
株価収益率:
-61.80
EPS:
-2.2979
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.68%
1か月 パフォーマンス:
-12.78%
6か月 パフォーマンス:
+8.51%
1年 パフォーマンス:
+130.58%
1日の値動き範囲:
$134.01
$142.78
1週間の範囲:
$134.01
$148.60
52週間の値動き範囲:
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
142.01 | 5.50B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | 開始されました | BofA Securities | Buy |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-02 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Neutral |
| 2023-12-14 | 開始されました | Maxim Group | Buy |
| 2023-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 開始されました | SVB Securities | Outperform |
| 2022-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-01 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Belite Bio Inc Adr (BLTE) 最新ニュース
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Canada
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress By Investing.com - Investing.com South Africa
Earnings Scheduled For May 20, 2026 - Sahm
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress - Investing.com
Belite Bio Q1 2026 Earnings Call Transcript - MarketBeat
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses By GuruFocus - Investing.com Canada
BLTE Stock Price, Quote & Chart | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Belite Bio Ramps Toward Tinlarebant Launch - TipRanks
Belite Bio Q1 Earnings Call Highlights - inkl
Belite Bio (BLTE) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Belite Bio beats Q1 2026 EPS estimates, stock dips - Investing.com
Belite Bio Releases Q1 2026 Financial Results - AlphaStreet
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base - TipRanks
Belite Bio Q1 Adjusted Loss Widens - marketscreener.com
Earnings Flash (BLTE) Belite Bio, Inc Posts Q1 Adjusted Loss $0.34 per Share, vs. FactSet Est of $-0.69 - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat By Investing.com - Investing.com Nigeria
Belite Bio stock gains 2% on first-quarter earnings beat - Investing.com
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - Caledonian Record
Belite Bio (NASDAQ: BLTE) starts tinlarebant NDA as Q1 2026 loss deepens - Stock Titan
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Belite Bio (BLTE) Is Down 6.6% After Swiss Orphan Status, FDA Filing Progress For Tinlarebant - Sahm
Belite Bio receives Swiss orphan drug status for tinlarebant By Investing.com - Investing.com Nigeria
Belite Bio receives Swiss orphan drug status for tinlarebant - Investing.com
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland - marketscreener.com
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - The Manila Times
Belite Bio (BLTE) CEO & Chairman reports 1.25M shares, including vested awards - Stock Titan
Transcript : Belite Bio, Inc Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results - marketscreener.com
Trading the Move, Not the Narrative: (BLTE) Edition - Stock Traders Daily
Belite Bio (BLTE) CSO exits 666 ADS in 10b5-1 stock sales - Stock Titan
Belite Bio (BLTE) CSO offloads 1,000 ADS in Rule 10b5-1 sales - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADSs in Rule 10b5-1 trades - Stock Titan
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com Nigeria
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $155,777 in shares - Investing.com
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart.com
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio Inc Adr (BLTE) 財務データ
収益
当期純利益
現金流量
EPS
Belite Bio Inc Adr (BLTE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MATA NATHAN L. | Chief Scientific Officer |
May 06 '26 |
Sale |
153.84 |
1,000 |
153,839 |
666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 05 '26 |
Sale |
155.50 |
1,000 |
155,502 |
1,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 04 '26 |
Sale |
155.64 |
1,000 |
155,636 |
2,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 01 '26 |
Sale |
155.78 |
1,000 |
155,778 |
3,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 30 '26 |
Sale |
156.97 |
1,000 |
156,973 |
4,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 29 '26 |
Sale |
155.82 |
1,000 |
155,817 |
5,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 28 '26 |
Sale |
159.16 |
1,000 |
159,162 |
6,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 27 '26 |
Sale |
162.64 |
1,000 |
162,641 |
7,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 24 '26 |
Sale |
159.56 |
1,000 |
159,556 |
8,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 23 '26 |
Sale |
166.28 |
1,000 |
166,284 |
9,666 |
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):